Events

Apr

INVO Seminar | SBIR Workshop

Chicago - 10:00 AM - 11:00 AM

For Northwestern community members (faculty, post docs, students) who would like to learn more about non-dilutive funding from the government:

An NIH expert, Stephanie Fertig (National Institute of Neurological Disorders and Stroke (NINDS)) will discuss and answer questions related to SBIR/STTR grants.

What is an SBIR/STTR?

What is the difference between an SBIR/STTR?

How do I find funding announcements for entrepreneurial resources?

What separates a good SBIR/STTR application from a bad SBIR/STTR application?

How can I improve my SBIR/STTR application?

In addition to this seminar, Stephanie Fertig is willing to meet with investigators in one-on-one conferences which will be scheduled on a first come/first serve basis. Please email Dimitra Georganopoulou (d-georganopoulou@northwestern.edu) if you are interested.

Stephanie J. Fertig is the Director, NINDS Small Business Programs in the Office of Translational Research at the National Institute of Neurological Disorders and Stroke (NINDS). During her almost 15 years at NIH she has led the development and implementation of multiple programs focused on small businesses and translational research. Currently, Ms. Fertig manages both the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which are congressionally mandated set-aside programs specifically for small business concerns. In addition, she co-leads the BRAIN Initiative team focused on training and dissemination of technologies.

Apr

How NU GoKidney’s Core B Can Help Your Research (Webinar)

Online - 12:30 PM - 1:30 PM

Effective translation of basic kidney research to kidney therapeutics remains challenging. NU GoKidney s Therapeutic Design & Development Core (Core B) state-of-the-art core resources and extensive expertise in novel cellular therapeutics development, virtual drug and biologics design, high-throughput screening platforms, and nanotechnology-based precision drug targeting.

How can you leverage the cutting-edge services of NU GoKidney s Therapeutic Design & Development Core (Core B) to advance your research?

Join our webinar with NU GoKidney s Core B to learn how researchers are using its research support and highly experienced experts to guide them to the most productive route for developing their conceptual advances to clinical therapeutics.

In this webinar you ll learn about:
NU GoKidney & it s mission
Ways the Therapeutic Design & Development Core (Core B) can support your research
How to work with Core B

Speakers
Jason Wertheim, MD, PhD
NU GoKidney Core B Director
Associate Professor of Surgery (Organ Transplantation) and McCormick School of Engineering
Follow him on Twitter @J_Wertheim1

James Mathew, PhD
NU GoKidney Core B Navigator
Research Professor of Surgery (Organ Transplantation) and Microbiology-Immunology

Irawati Kandela, PhD
NU GoKidney Core B Collaborator
Assistant Director of Developmental Therapeutics Core, Chemistry Life Processes Institute

Carlos Vanoye, PhD
NU GoKidney Core B Collaborator
Research Associate Professor of Pharmacology

Apr

Renal Grand Rounds

Chicago - 12:00 PM - 1:00 PM

Presented By:

Deparment of Medicine-Division of Nephrology Renal Grand Rounds

May

Renal Grand Rounds

Chicago - 12:00 PM - 1:00 PM

Presented By:

Laurence H. Beck, Jr., MD, PhD

Associate Professor of Medicine

Chicago - 12:00 PM - 1:00 PM

Presented By:

Deparment of Medicine-Division of Nephrology Renal Grand Rounds

May

Renal Grand Rounds

Chicago - 12:00 PM - 1:00 PM

Presented By:

Deparment of Medicine-Division of Nephrology Renal Grand Rounds

May

INVO & Lakeside Discovery Seminar | Transforming Antibodies into Drugs

Off-Campus - 3:30 PM - 6:00 PM

Please join INVO and Lakeside Discovery for this May seminar which aims to provide insight into antibody therapeutic discovery and development in the academic setting. Experts will examine the state-of-the-art science in the field and provide details on resources available at Northwestern to accelerate antibody discovery.

Over the past 5 years, recombinant antibodies have been established at a growing rate into clinical practice for the treatment of diseases ranging from cancer to autoimmune and infectious diseases. The seminar will cover various aspects related to the commercialization of therapeutic antibodies, with the hope of fostering PI interest in future submissions to Lakeside Discovery, a drug discovery collaboration between Northwestern University and Deerfield Management.

3:30pm Welcome and Introductions
3:35pm Lakeside Discovery Transforming Discoveries into Drugs
4:00pm Current and Future Trends in Therapeutic Antibodies
4:30pm Q&A Session
5-6:00pm Reception

OUR SPEAKERS

William Slattery
Partner, Deerfield Management
Joint Steering Committee Member, Lakeside Discovery

Mr. Slattery is a Partner on the Biotherapeutics group at Deerfield, which he joined in 2000. He began his professional career studying immune system complications associated with End Stage Renal Disease. Prior to joining Deerfield, Mr. Slattery was a senior healthcare analyst between 1990 and 2000 at Amerindo Investment Advisors overseeing biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Mr. Slattery is the Chairman of Gilda s Club New York City, a non-profit organization supporting cancer patients and their families. Mr. Slattery has a degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.

Larry Green, Ph.D.
Founder and CEO, Ablexis
Co-inventor, AlivaMab Mouse
CEO, AlivaMab Discovery Services

Larry is CEO and founder of Ablexis, and co-inventor of the AlivaMab Mouse. He also serves as CEO of AlivaMab Discovery Services. Larry has over a quarter century of experience in designing, creating and using transgenic mouse platforms for antibody drug discovery. Larry joined Aliva Biopharmaceuticals, Inc. in 2008 as CEO, where he optimized the blueprint for AlivaMab Mouse and procured a Series A financing, resulting in the founding of Ablexis, LLC in 2009. Prior to joining Aliva, he was a co-inventor of the XenoMouse technology at Cell Genesys and was a scientific founder of the spin-out of Abgenix, where he served as designer and team leader for making improved versions of the XenoMouse technology, director of antibody discovery operations, leader of the collaborations group, and the senior research representative on joint steering committees in alliances with Amgen, AstraZeneca, Pfizer amongst other companies.

Larry is an inventor on several dozen patents covering immunoglobulin transgenic mice and therapeutic antibodies. He received his Ph.D. in Molecular and Cellular Biology from the University of Wisconsin-Madison and did postdoctoral research at the University of Colorado at Boulder and Stanford University.

Joseph Pearlberg, M.D., Ph.D.
Vice President of Scientific Affairs, Deerfield Management
Joint Steering Committee Member, Lakeside Discovery

Dr. Pearlberg is the Vice President of Scientific Affairs and is on the Biotherapeutics group at Deerfield which he joined in July 2017. Prior to joining Deerfield, he was the Vice President of Clinical Development at Infinity Pharmaceuticals from December 2015 until July 2017. Prior to Infinity Pharmaceuticals, Dr. Pearlberg worked as a Medical Director in the oncology unit of Sanofi from November 2010 until September 2014. Dr. Pearlberg received his M.D. at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. Dr. Pearlberg also received his Ph.D. in molecular biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He also holds a B.A. in Biochemistry from the University of Pennsylvania.

Amie Phinney, Ph.D., M.B.A.
Director of Alliance Management, Lakeside Discovery

Amie joined Lakeside Discovery in August 2018. Amie brings extensive experience in drug discovery, preclinical development and alliance management. Amie began her pharmaceutical career as a Senior Scientist, Preclinical Project Director and Program Manager in the Neuroscience Division of Solvay Pharmaceutical in the Netherlands. Later at Abbott Labs and AbbVie Pharmaceuticals, Amie continued to develop her expertise in the development of drug candidates, specializing in partnered discovery projects. In her roles as a Collaboration Project Manager, Operations Director and Alliance Leader, Amie successfully led multi-party, cross-functional project teams through all stages of drug discovery. Before joining industry, Amie was a research fellow at the University of Toronto and the Free University of Amsterdam. She holds a PhD in Biomedical Research from the University of Basel in Switzerland and an MBA from Lake Forest Graduate School of Management in Illinois.

May

INVO Seminar | Fundamental of Startup Financing

Chicago - 12:00 PM - 1:00 PM

Northwestern Faculty, Staff and Students

Presented By:

Deparment of Medicine-Division of Nephrology Renal Grand Rounds